Michael Reade will present the CLIP II trial results at CCR Down Under 2025.
CLIP II is a phase III, multicentre, blinded, randomized non-inferiority trial comparing cryopreserved platelets versus conventional liquid-stored platelets for treating surgical bleeding, especially in high-risk adult cardiac surgery patients.
Cryopreservation (-80°C, with DMSO) can extend platelet shelf-life from just 5–7 days to up to two years, offering potential logistical advantages for smaller, rural, or military hospitals where liquid platelets are hard to maintain.
Approximately 808 patients will be enrolled across Australia and New Zealand (11-12 hospitals in Australia, 5 in NZ), with up to three units of study platelets given if a surgeon deems platelet transfusion necessary.
The primary endpoint is blood loss via surgical drains during the first 24 hours after ICU admission post-surgery; secondary endpoints include safety, transfusion needs, cost, ICU/hospital stay, and mortality.
If cryopreserved platelets are shown to be non-inferior to liquid platelets, this could enable a major shift in blood service practice—improving access, reducing waste, and enhancing preparedness in settings that currently struggle with platelet supply.
CCR Blog
The Etomidate Conundrum
Induction for rapid sequence intubation (RSI) in the critically ill often feels like the swing of a pendulum. Toward etomidate—hemodynamic poise, clean hypnosis, and familiar dosing. Back toward ketamine—sympathomimetic support, bronchodilation, and neuro-myths in slow retreat. The science, at times, looks just as mercurial. This review examines the terrain with a steady eye: what goes wrong when we intubate the critically ill; why physiology, not just anatomy, governs risk; what etomidate and ketamine truly offer; what the best comparative trials show; and a look forward to the upcoming results of the RSI trial at CCR Down Under 2025.
Added September 4th
Narrative Reviews
Narrative Review
Guideline
Randomised Controlled Trial
Narrative Review
Systematic Review & Meta Analysis
Randomised Controlled Trial
TIGRIS Trial Result Press Release - Polymyxin B Hemoadsorption Therapy for Endotoxic Septic Shock
- Results exceed prespecified primary endpoint of 95% posterior probability of benefit for PMX on 28-day mortality
added August 13th
Randomised Controlled Trial
Paper of the Day
Saturday, September 13th
Join us to read one paper per day and cover the spectrum of critical care across 2025. Previous papers of the day are available here.
Newsletter 717
Critical Care Reviews Newsletter 717, bringing you the best critical care research and open access articles for the week September 1st to 7th.
Subscriptions are available to individuals and departments.
added September 7th
Highlighted Narrative Reviews
With thousands of open access narrative reviews listed across the website, CCR provides a comprehensive educational resource. We'll highlight one topic here every few days. Today, we look at Acute Kidney Injury
added August 20th
Foundational Trials
It's the latest in our Foundational Trials collection, looking at the trials which underpin contemporary critical care practice
added August 19th
Highlighted Guidelines
Need a guideline, or just want to refresh your knowledge on the evidence-based management of a particular condition? We provide more up-to-date guidelines than any other critical care resource. Have a look at our ARDS Guideline section
added August 12th
Registration has opened for CCR Down Under in Melbourne, on December 9th and 10th, again at the Edge in Federation Square.
We aim to bring another set of fantastic international critical care trials to Australia. If you are interested in the science underlying clinical practice, this is the meeting for you.
We're delighted to be partnering once again with the Alfred Intensive Care Academic Centre, and this year, with Monash University.
If you missed the presentations last December, the presentations of the so far published trials are available here.
